TABLE I.
Leukemia cell subsets enriched with leukemia stem cells in T-cell acute lymphoblastic leukemia
| Reference | Cell-surface markers | Tumour type | Minimal tumourigenic dose (cells) | Transplant technique | Strain of recipient mice |
|---|---|---|---|---|---|
| Cox et al., 200715 | CD34+CD4− or CD34+CD7– | Human | 104 | Intravenous injection | Immunodeficient (NSGa) |
| Guo et al., 200819 | c-KitmidCD3+Lin− | Pten−/−induced mouse leukemia | 102 | Intravenous injection | Immunodeficient (SCID) |
| Armstrong et al., 200917 | CD7+CD1a– | Human | 103 | Intrafemoral injection | Immunodeficient (NSGa) |
| McCormack et al., 201020, Tremblay et al., 201021 | CD4−CD8−CD44−CD25+ (DN3), CD4−CD8−CD44−CD25− (DN4) | TAL1/SCLand LMO1/2induced mouse model | 103 | Intravenous injection | Immunodeficient (Rag1−/−) |
| Giambra et al., 201222 | ROSlow | Human | 105 | Intravenous injection | Immunodeficient (NSGa) |
| ROSlowCD44+ | Notch1 ΔE-induced mouse leukemia | 102 | Intravenous injection | Syngeneic (C57BL/6) | |
| ROSlowCD44+ | KrasG12D-induced mouse leukemia | 103 | Intravenous injection | Syngeneic (C57BL/6) |
a
The Jackson Laboratory, Bar Harbor, ME, U.S.A.
NSG = NOD SCID gamma; SCID = severe combined immunodeficiency; DN3/4 = double-negative 3/4; TAL1 = T-cell acute lymphocytic leukemia 1; LMO1/2 = LIM domain only 1/2; ROS = reactive oxygen species.